|
TTC28 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.63530000441403E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.39720000003063E-06 |
| Normal-vs-Stage2 |
2.050300E-02 |
| Normal-vs-Stage3 |
1.16810000005962E-07 |
| Normal-vs-Stage4 |
1.18270000004639E-06 |
| Stage1-vs-Stage2 |
1.167020E-01 |
| Stage1-vs-Stage3 |
1.695370E-01 |
| Stage1-vs-Stage4 |
1.440420E-01 |
| Stage2-vs-Stage3 |
1.438210E-02 |
| Stage2-vs-Stage4 |
1.590060E-02 |
| Stage3-vs-Stage4 |
8.649400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.50479999969389E-08 |
| Normal-vs-AfricanAmerican |
7.097100E-03 |
| Normal-vs-Asian |
8.44930000000188E-05 |
| Caucasian-vs-AfricanAmerican |
6.343800E-01 |
| Caucasian-vs-Asian |
9.087400E-01 |
| AfricanAmerican-vs-Asian |
6.163400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.021780E-04 |
| Normal-vs-Female |
1.70189999870729E-08 |
| Male-vs-Female |
4.391000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.53522999999378E-05 |
| Normal-vs-Age(41-60Yrs) |
1.54099999982726E-07 |
| Normal-vs-Age(61-80Yrs) |
1.63441999999625E-05 |
| Normal-vs-Age(81-100Yrs) |
4.488200E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.274000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.054800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.842800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.588400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.993000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.121600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.595500E-03 |
| Classical-VS-Follicular |
3.780600E-01 |
| Classical-VS-Other |
5.972300E-02 |
| Classical-VS-Normal |
7.1345999996808E-07 |
| Tall-VS-Follicular |
4.062600E-03 |
| Tall-VS-Other |
3.764000E-01 |
| Tall-VS-Normal |
1.23530000006866E-07 |
| Follicular-VS-Other |
4.956100E-02 |
| Follicular-VS-Normal |
1.142050E-03 |
| Other-VS-Normal |
1.277240E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.57940000000689E-06 |
| Normal-vs-N1 |
2.39089999999331E-05 |
| N0-vs-N1 |
4.642600E-01 |
|
|
